PERIOD PREVALENCE OF MAJOR COMORBIDITIES FOLLOWING THE DIAGNOSIS OF GRAVES’ DISEASE: A NATIONWIDE COHORT STUDY IN SOUTH KOREA
Author(s)
Minsung Kim, BS1, Hae Sun Suh, MA, MS, PhD2;
1Graduate School, Kyung Hee University, Department of Regulatory Science, Seoul, Korea, Republic of, 2Kyung Hee University, College of Pharmacy, Seoul, Korea, Republic of
1Graduate School, Kyung Hee University, Department of Regulatory Science, Seoul, Korea, Republic of, 2Kyung Hee University, College of Pharmacy, Seoul, Korea, Republic of
OBJECTIVES: Graves’ disease (GD) is an autoimmune disorder associated with a range of comorbidities. This study evaluated the period prevalence of six major comorbidities following the diagnosis of GD using nationwide data from South Korea.
METHODS: This retrospective cohort study was conducted using the Health Insurance Review and Assessment Service database in Korea from January 2018 to June 2024. Patients with newly diagnosed GD were identified based on at least two claims with ICD-10 code E05 and at least 180 days of antithyroid drug prescriptions between January 1, 2019, and December 31, 2023. Six major comorbidities including Graves’ ophthalmopathy, atrial fibrillation or flutter, heart failure, osteoporosis, fractures, and autoimmune diseases, were identified using ICD-10 codes until June 30, 2024. The period prevalence of each comorbidity was calculated as the proportion of patients with newly diagnosed GD during the study period, overall and by sex.
RESULTS: Out of 1,336,375 patients, a total of 136,626 patients with GD were identified. The mean age at diagnosis was 48.0 ± 16.1 years, and 69.4% were female. The prevalence of comorbidities was 6.15% for Graves’ ophthalmopathy, 5.84% for atrial fibrillation or flutter, 2.03% for heart failure, 15.49% for osteoporosis, 5.91% for fractures, and 9.24% for autoimmune diseases. Graves’ ophthalmopathy (6.50 vs 5.30%), fractures (6.47% vs 4.66%), osteoporosis (20.45% vs 4.25%), and autoimmune diseases (10.12% vs 7.22%) were more prevalent among female, whereas atrial fibrillation or flutter was more prevalent among male (4.66% vs 8.51%). Heart failure (2.01% vs 2.03%) showed similar prevalence between sexes.
CONCLUSIONS: This study assessed the prevalence of ophthalmologic, cardiovascular, skeletal, and autoimmune comorbidities among patients with GD and showed that the prevalence of these comorbidities differed by sex. These findings highlight the importance of considering sex differences in the clinical assessment of patients with GD.
METHODS: This retrospective cohort study was conducted using the Health Insurance Review and Assessment Service database in Korea from January 2018 to June 2024. Patients with newly diagnosed GD were identified based on at least two claims with ICD-10 code E05 and at least 180 days of antithyroid drug prescriptions between January 1, 2019, and December 31, 2023. Six major comorbidities including Graves’ ophthalmopathy, atrial fibrillation or flutter, heart failure, osteoporosis, fractures, and autoimmune diseases, were identified using ICD-10 codes until June 30, 2024. The period prevalence of each comorbidity was calculated as the proportion of patients with newly diagnosed GD during the study period, overall and by sex.
RESULTS: Out of 1,336,375 patients, a total of 136,626 patients with GD were identified. The mean age at diagnosis was 48.0 ± 16.1 years, and 69.4% were female. The prevalence of comorbidities was 6.15% for Graves’ ophthalmopathy, 5.84% for atrial fibrillation or flutter, 2.03% for heart failure, 15.49% for osteoporosis, 5.91% for fractures, and 9.24% for autoimmune diseases. Graves’ ophthalmopathy (6.50 vs 5.30%), fractures (6.47% vs 4.66%), osteoporosis (20.45% vs 4.25%), and autoimmune diseases (10.12% vs 7.22%) were more prevalent among female, whereas atrial fibrillation or flutter was more prevalent among male (4.66% vs 8.51%). Heart failure (2.01% vs 2.03%) showed similar prevalence between sexes.
CONCLUSIONS: This study assessed the prevalence of ophthalmologic, cardiovascular, skeletal, and autoimmune comorbidities among patients with GD and showed that the prevalence of these comorbidities differed by sex. These findings highlight the importance of considering sex differences in the clinical assessment of patients with GD.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EPH144
Topic
Epidemiology & Public Health
Disease
SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity), SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)